Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: A clinical practice survey nested in the CESAME cohort

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 188-195

  Vienne, A ^a   Simon, T ^b   Cosnes, J ^a   Baudry, C ^c   Bouhnik, Y ^c   Soule J C ^c   Chaussade, S ^c   Marteau, P ^c   Jian, R ^c   Delchier, J C ^d   Coffin, B ^e   Admane, H ^b   Carrat, F ^f   Drouet, E ^b   Beaugerie, L ^c,f  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL LOUIS MOURIER   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; CORTICOSTEROID DERIVATIVE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; CANCER STAGING; CHROMOENDOSCOPY; CLINICAL PRACTICE; COHORT ANALYSIS; COLON BIOPSY; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ENTERITIS; FEMALE; FOLLOW UP; FRANCE; GASTROINTESTINAL DYSPLASIA; HEALTH SURVEY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROCTOCOLECTOMY; QUESTIONNAIRE; REVIEW; SEX DIFFERENCE; ULCERATIVE COLITIS; UNIVERSITY HOSPITAL;

ADULT; COHORT STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; QUESTIONNAIRES; TIME FACTORS;

EID: 79959377068     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04711.x     Document Type: Review

References (34)

1. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35. (Pubitemid 32234798)
2. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 2008; 6: 993-8.
3. Beaugerie L, Seksik P, Bouvier AM, et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME cohort. Gastroenterology 2009; 136: A-54.
4. Collins PD, Mpofu C, Watson AJ, Rhodes JM,. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; 2: CD000279.
5. Eaden JA, Mayberry JF,. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51 (Suppl. 5): V10-2. (Pubitemid 35222898)
6. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-60. (Pubitemid 36169269)
7. Itzkowitz SH, Present DH,. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 314-21. (Pubitemid 40439686)
8. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85. (Pubitemid 39062279)
9. Biancone L, Michetti P, Travis SP, et al. European evidence based consensus on the management of ulcerative colitis: special situations. J Crohn's Colitis 2008; 2: 63-92. (Pubitemid 351179489)
10. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-89.
11. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-45.
12. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
13. Eaden JA, Ward BA, Mayberry JF,. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000; 51: 123-8. (Pubitemid 30094501)
14. Gearry RB, Wakeman CJ, Barclay ML, et al. Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in New Zealand. Dis Colon Rectum 2004; 47: 314-22. (Pubitemid 38280583)
15. Kaplan GG, Heitman SJ, Hilsden RJ, et al. Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis 2007; 13: 1401-7. (Pubitemid 350206853)
16. Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010; 139: 1511-8.
17. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
18. Richards SH, Campbell JL, Dickens A,. Does the method of administration influence the UK GMC patient questionnaire ratings? Prim Health Care Res Dev 2011; 12: 68-78.
19. van Rijn AF, Fockens P, Siersema PD, et al. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol 2009; 15: 226-30.
20. Thomas T, Nair P, Dronfield MW, et al. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol 2005; 17: 1317-24. (Pubitemid 41830452)
21. Kottachchi D, Yung D, Marshall JK,. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol 2009; 23: 613-7.
22. Oxelmark L, Nordstrom G, Sjoqvist U, et al. Anxiety, functional health status, and coping ability in patients with ulcerative colitis who are undergoing colonoscopic surveillance. Inflamm Bowel Dis 2004; 10: 612-7. (Pubitemid 39276470)
23. Robinson RJ, Hart AR, Mayberry JF,. Cancer surveillance in ulcerative colitis: a survey of patients' knowledge. Endoscopy 1996; 28: 761-2. (Pubitemid 27032732)
24. Koobatian GJ, Choi PM,. Safety of surveillance colonoscopy in long-standing ulcerative colitis. Am J Gastroenterol 1994; 89: 1472-5. (Pubitemid 24313035)
25. Eloubeidi MA, Wallace MB, Desmond R, et al. Female gender and other factors predictive of a limited screening flexible sigmoidoscopy examination for colorectal cancer. Am J Gastroenterol 2003; 98: 1634-9. (Pubitemid 36875360)
26. Wong MC, Tsoi KK, Ng SS, et al. A comparison of the acceptance of immunochemical faecal occult blood test and colonoscopy in colorectal cancer screening: a prospective study among Chinese. Aliment Pharmacol Ther 2010; 32: 74-82.
27. Choi PM, Zelig MP,. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950-4.
28. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. Histopathology 2007; 50: 574-83. (Pubitemid 46495833)
29. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33. (Pubitemid 20366527)
30. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-9. (Pubitemid 20264156)
31. Bergeron V, Vienne A, Sokol H, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010; 105: 1405-11.
32. Van Assche G, Dignass A, Reinisch W,. The second European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn's Colitis 2010; 4: 63-88.
33. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53. (Pubitemid 30088290)
34. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009; 104: 2222-32.